Premium
Successful treatment of delayed pressure urticaria with 300 mg of omalizumab every 14 days
Author(s) -
Saylam Kurtipek Gulcan,
Zekey Emre,
Tuncez Akyurek Fatma
Publication year - 2021
Publication title -
journal of cosmetic dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.626
H-Index - 44
eISSN - 1473-2165
pISSN - 1473-2130
DOI - 10.1111/jocd.13764
Subject(s) - omalizumab , medicine , chronic urticaria , dermatology , immunoglobulin e , immunology , antibody
Delayed pressure urticaria is a rare form of chronic inducible urticaria characterized by erythematous‐painful plaques that develop in areas of the skin exposed to prolonged pressure. Its treatment is very difficult, and its response to antihistamines is variable. Cases of delayed pressure urticaria, which have been completely controlled with the use of omalizumab in recent years, have been reported.